Thyrocare Technologies’ shares down 67%? Here’s why investors shouldn’t worry

Shares of Thyrocare Technologies witnessed a steep decline of 66.7% in Friday’s early trade to the day’s low of Rs 492, from their closing price of Rs 1,473.90 on Thursday, as the stock began trading ex-bonus following the company’s recently announced 2:1 bonus issue.

The sudden fall in share price, while appearing alarming at first glance, is a standard market reaction to the stock turning ex-bonus and does not reflect any change in the company’s fundamentals or investor sentiment.

The correction in price comes in the wake of the company’s decision to issue two bonus equity shares for every one existing share of face value Rs 10, fully paid-up. The bonus shares have been issued in the ratio of 2:1, effectively tripling the number of outstanding shares in the market.

This move was recommended by the Board of Directors, approved by shareholders, and officially communicated to the exchanges. The record date for determining shareholder eligibility was fixed as Friday, November 28, 2025.

As per standard stock exchange rules, shares of a company turn ex-bonus one trading day before the record date. In Thyrocare’s case, the ex-bonus and record date both fell on November 28, 2025. Investors whose names appeared in the company’s records by the end of trading on this date became eligible to receive the bonus shares.

The deemed date of allotment of these bonus shares has been set as Monday, December 1, and they are expected to be available for trading from Tuesday, December 2.The company clarified in its filing that the bonus shares will rank pari-passu with existing equity shares in all respects, including dividend entitlement and voting rights. The stated objective of the bonus issue was to enhance liquidity and promote broader retail participation.This is the first-ever bonus issue declared by Thyrocare Technologies, according to Trendlyne data.

Thyrocare Technologies is a prominent player in India’s healthcare diagnostics industry, offering a range of affordable diagnostic services to patients, laboratories, and hospitals across the country.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)